一、中文名称：
Research Grade Blisibimod，科研级贝利西单抗，精品蛋白抗体试剂盒
二、产品描述
Blisibimod (A 623) 是一种有效和选择性的四价B细胞激活因子(BAFF)抑制剂。Blisibimod可用于系统性红斑狼疮(SLE)的研究。
三、产品详情
名称：Research Grade Blisibimod，科研级贝利西单抗，体内中和抗体，活性抗体
货号：DHJ85305
表达系统：Mammalian Cells
种属反应性：Human
宿主：Human
同种型：Fusion - [peptide 16-mer - peptide 19-mer]2 - IGHG1 Fc (Fragment constant)
靶标：BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor
浓度：0.5 mg/ml
内毒素水平：Please contact with the lab for this information.
纯度：>95% as determined by SDS - PAGE.
纯化方式：Protein A/G purified from cell culture supernatant.
Accession号：Q9Y275
克隆号：Blisibimod
应用：Research Grade Biosimilar
状态：Liquid
保存溶液：0.01M PBS, pH 7.4.
稳定性和存储：Use a manual defrost freezer and avoid repeated freeze - thaw cycles. Store at 4°C short term (1 - 2 weeks). Store at -20°C 12 months. Store at -80°C long term.
别名：A – 623
四、参考文献：
Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.PMID:27051973
Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.PMID:28331294
A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP).PMID:37755547
The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.PMID:23684423
Advances in natural products and antibody drugs for SLE: new therapeutic ideas.PMID:37492083
Emerging B-Cell Therapies in Systemic Lupus Erythematosus.PMID:33488082
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.PMID:29563108
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.PMID:26290435
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.PMID:24748629
Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.PMID:24521424
详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司
网址：https://www.biolabreagent.com/product/99/5729.html
武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
